← PTC THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $82.7m | $194.4m | $264.7m | $307.0m | $380.8m | $538.6m | $698.8m | $937.8m | $806.8m | $1.7b | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | $264.7m | $307.0m | — | — | — | — | — | — | |
| Cost of Revenue | $62.0m | $4.6m | $198.6m | $12.1m | $285.6m | $403.9m | $524.1m | $703.4m | $605.1m | $863.7m | |
| Gross Profit (Calculated) (derived) | $20.7m | $189.8m | $66.2m | $294.8m | $95.2m | $134.6m | $174.7m | $234.5m | $201.7m | $866.9m | |
| Operating Expenses | $214.8m | $258.7m | $380.4m | $548.1m | $812.5m | $913.0m | $1.1b | $1.4b | $1.1b | $863.7m | |
| Operating Income (Loss) | ($132.1m) | ($64.3m) | ($115.7m) | ($241.2m) | ($431.8m) | ($374.4m) | ($447.4m) | ($439.5m) | ($302.6m) | $866.9m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | — | $15.4m | $22.9m | $27.6m | $36.9m | $54.8m | $116.6m | $222.6m | $60.7m | $24.7m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | $4.4m | — | — | |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | ($16.9m) | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $132.1m | ($54.6m) | ($68.5m) | ($231.9m) | ($452.5m) | ($487.7m) | ($591.1m) | ($784.7m) | ($598.8m) | $1.2b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($141.5m) | ($77.7m) | ($128.1m) | ($239.9m) | ($402.9m) | ($518.3m) | ($587.5m) | ($696.1m) | ($363.1m) | $696.6m | |
| Net Income (Loss) Attributable to Parent | ($142.1m) | ($79.0m) | ($128.1m) | ($251.6m) | ($438.2m) | ($523.9m) | ($559.0m) | ($626.6m) | ($363.3m) | $682.6m | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($142.1m) | ($79.0m) | ($128.1m) | ($251.6m) | ($438.2m) | ($523.9m) | ($559.0m) | ($626.6m) | ($363.3m) | $682.6m | |
| Earnings Per Share, Basic | — | — | — | ($4.27) | ($6.64) | ($7.43) | ($7.79) | ($8.37) | ($4.73) | $8.58 | |
| Earnings Per Share, Diluted | ($4.17) | ($2.02) | ($2.75) | ($4.27) | ($6.64) | ($7.43) | ($7.79) | ($8.37) | ($4.73) | $7.78 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 70.5m | 71.7m | 74.8m | 76.8m | 79.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 70.5m | 71.7m | 74.8m | 76.8m | 88.3m | |
| Research and Development Expense | $117.6m | $117.5m | $172.0m | $257.5m | $477.6m | $540.7m | $651.5m | $666.6m | $534.5m | $455.2m | |
| General and Administrative Expense | $97.1m | $121.3m | — | — | — | — | — | — | — | — | |
| Selling, General and Administrative Expense | $97.1m | $121.3m | $153.5m | $202.5m | $245.2m | $285.8m | $326.0m | $332.5m | $300.9m | $347.1m | |
| Other Nonoperating Income (Expense) | ($1.2m) | ($1.3m) | $129k | $13.7m | $85.2m | ($57.9m) | ($49.2m) | $10.1m | $6.5m | ($18.1m) | |
| Operating Lease, Expense | — | — | $2.7m | $6.0m | $15.3m | $21.4m | $25.2m | $29.0m | $24.9m | $21.1m | |
| Income Tax Expense (Benefit) | $569k | $1.3m | ($29k) | $11.7m | $35.2m | $5.6m | ($28.5m) | ($69.5m) | $176k | $14.0m | |
| Interest Income (Expense), Nonoperating, Net | ($8.3m) | ($12.1m) | ($12.6m) | ($12.5m) | ($56.4m) | ($86.0m) | ($90.9m) | ($129.2m) | ($167.0m) | ($152.2m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.